TY - JOUR
T1 - Vandetanib in advanced medullary thyroid cancer
T2 - Review of adverse event management strategies
AU - Grande, Enrique
AU - Kreissl, Michael C.
AU - Filetti, Sebastiano
AU - Newbold, Kate
AU - Reinisch, Walter
AU - Robert, Caroline
AU - Schlumberger, Martin
AU - Tolstrup, Lærke K.
AU - Zamorano, Jose L.
AU - Capdevila, Jaume
N1 - Funding Information:
received a consulting fee/honorarium from GETHI, support for travel to meetings from GETHI, and a grant from GETHI Group.
Funding Information:
drafts under direction from the authors. Manuscript development was conducted without input from AstraZeneca. The services provided by iMed Comms were funded by the educational grant provided by AstraZeneca. Funding for the article processing charges and slide deck was provided by AstraZeneca. Enrique Grande is the guarantor for this article, and takes responsibility for the integrity of the work as a whole.
PY - 2013/11/1
Y1 - 2013/11/1
N2 - Introduction: Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms, effective management of related adverse events (AEs) is vital to ensure patient compliance and maximize clinical benefit with vandetanib therapy. Methods: This expert meeting-based review aims to summarize published data on AEs associated with vandetanib therapy and to provide clinicians with specific practical guidance on education, monitoring, and management of toxicities induced in patients treated with vandetanib in advanced and metastatic MTC. The content of this review is based on the expert discussions from a multidisciplinary meeting held in October 2012. Results: Characteristics, frequency, and risk data are outlined for a number of dermatological, cardiovascular, gastrointestinal, and general AEs related to vandetanib treatment. Preventive strategies, practical treatment suggestions, and points for clinical consideration are provided. Conclusions: Good patient and team communication is necessary for the prevention, early detection, and management of AEs of vandetanib. Physicians, nurses, and other healthcare providers play a critical role in providing AE management and patient support to optimize outcomes with vandetanib in MTC.
AB - Introduction: Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms, effective management of related adverse events (AEs) is vital to ensure patient compliance and maximize clinical benefit with vandetanib therapy. Methods: This expert meeting-based review aims to summarize published data on AEs associated with vandetanib therapy and to provide clinicians with specific practical guidance on education, monitoring, and management of toxicities induced in patients treated with vandetanib in advanced and metastatic MTC. The content of this review is based on the expert discussions from a multidisciplinary meeting held in October 2012. Results: Characteristics, frequency, and risk data are outlined for a number of dermatological, cardiovascular, gastrointestinal, and general AEs related to vandetanib treatment. Preventive strategies, practical treatment suggestions, and points for clinical consideration are provided. Conclusions: Good patient and team communication is necessary for the prevention, early detection, and management of AEs of vandetanib. Physicians, nurses, and other healthcare providers play a critical role in providing AE management and patient support to optimize outcomes with vandetanib in MTC.
KW - Adverse effects
KW - Antineoplastic agents/adverse effects
KW - Cardiovascular
KW - Dermatology
KW - Medullary thyroid cancer
KW - Medullary thyroid carcinoma
KW - Patient safety
KW - Piperidines/therapeutic use
KW - Protein kinase inhibitors
KW - Thyroid neoplasms/drug therapy
KW - Vandetanib
UR - http://www.scopus.com/inward/record.url?scp=84890125211&partnerID=8YFLogxK
U2 - 10.1007/s12325-013-0069-5
DO - 10.1007/s12325-013-0069-5
M3 - Review article
C2 - 24249433
AN - SCOPUS:84890125211
SN - 0741-238X
VL - 30
SP - 945
EP - 966
JO - Advances in Therapy
JF - Advances in Therapy
IS - 11
ER -